IL3-zetakine-based T-cell therapy (Vor Biopharma)

N/A

Report date: 2025/03/20 15:19:10

Base Information

Drug NameIL3-zetakine-based T-cell therapy (Vor Biopharma)

Drug Alias Nameanti-CD123 zetakine-based T-cell therapy (Vor Biopharma)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionInterleukin-3 receptor subunit alpha modulators

TargetsInterleukin-3 receptor subunit alpha

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesVor Biopharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesVor Biopharma Inc

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A